Fourth protease inhibitor hits the market.
D017277:Drug Approval; D016527:Drug Costs; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D006801:Humans; D007546:Isoquinolines / Q000627:therapeutic use*; D019888:Nelfinavir; D013451:Sulfonic Acids / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
D017320:HIV Protease Inhibitors; D007546:Isoquinolines; D013451:Sulfonic Acids; D019888:Nelfinavir